line

News

Innovative Science Affordable Medicine

NEWS

WMBIO Signs MOU with Korea Drug Development Fund (KDDF)

Author
admin
Date
2019-03-19 09:28
Views
479


WMBIO Signs MOU with Korea Drug Development Fund (KDDF)


KDDF


Wellmarker Bio Co. Ltd., has signed a research MOU with KDDF (Korea Drug  Development Fund) on March 14, 2019 to develop drug that could overcome colon cancer with Erbitux resistant. This is a follow-up project of KDDF’s ‘Drug development Research for Overcoming Erbitux-resistant Colon Cancer’ which has first initiated in May, 2017. Currently, Wellmarker Bio is verifying predictive biomarker that can predict drug development and drug response of the colon cancer patients that showed resistance to a targeted therapy known as Erbitux. Based on this, Wellmarker Bio is also performing additional research to extend indications for other types of carcinoma.


Dong-Hoon Jin, president and CEO of Wellmarker Bio, stated that “Since our first-in-class anticancer drugs based on predictive biomarkers are showing high efficacy in cancer, I believe we could license-out to foreign companies earlier than expected.”